Collaboration with COR2ED – HCC CONNECT

June 18, 2023

DiCE is pleased to collaborate with COR2ED, a provider of Independent Medical Education.  To stay up-to-date in Hepatocellular Carcinoma (HCC) please visit the COR2ED website to view these 2 educational programmes:

Experts Knowledge Share: Treatment Options for HCC Patients Not Eligible for or Progressed on IO

Watch the video of experts discussing immunotherapy (IO) as a 1st-line treatment for advanced HCC and options if patients are not eligible for 1st-line IO.  The panel also addresses the right time to switch to 2nd-line treatments. The video ends with an engaging Q&A where the experts answer pressing questions.  The video has been divided into four digestible chapters.

Watch the video replay


Micro-learning: The Use of Immunotherapy in HCC

This accredited micro-learning consists of two modules. Each module includes a short, animated video and downloadable resources.  Module 1 covers the efficacy and safety of IO and IO combinations and where they fit in the treatment landscape, how to understand the survival curve and how to identify and manage immune-related adverse events (irAE).  Module 2 focuses on subgroup analyses and explains how to assess liver function using the Albumin-Bilirubin (ALBI) scoring system to evaluate a patient’s eligibility for IO treatment and how to understand the safety and efficacy data in the different subgroups.


Take the micro learning

Module 1


Take the micro learning

Module 2

Lili Gundelach

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.